Acute myeloid leukaemia.
There has been considerable progress in the understanding and treatment of childhood acute myeloid leukaemia over the past two decades. In particular, cyto- and molecular genetics offer the potential for more specific diagnosis of what is basically a heterogeneous disease. To date treatment has been based on a steady increase in cytotoxic chemotherapy with or without the addition of bone marrow transplantation. Randomised therapeutic trials are difficult to perform in what is a rare disease. The best way forward is for paediatric trial groups worldwide to collaborate in developing common, or parallel, therapeutic protocols.
Stevens
R F
RF
Royal Manchester Children's Hospital, Manchester, UK.
D000208:Acute Disease; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction